Daily Cardiology Research Analysis
Analyzed 148 papers and selected 3 impactful papers.
Summary
Analyzed 148 papers and selected 3 impactful articles.
Selected Articles
1. An integrated cell atlas of 2.4 million cardiac cells across 209 individuals in health and disease.
HeartMap integrates nine single-nucleus RNA-seq datasets to create a 2.4-million–cell atlas across 209 adult hearts, eight regions, and seven health/disease states. It identifies robust disease signatures (for example in dilated cardiomyopathy) and distinct activated fibroblast populations enriched for COL22A1 or TNC with variable prevalence across cardiomyopathies, providing a standardized resource for mechanistic discovery.
Impact: This resource-level integration sets a new standard for single-cell cardiac biology and enables cross-study, cross-region comparisons to pinpoint disease-relevant cell states and targets.
Clinical Implications: While not immediately practice-changing, HeartMap facilitates mechanistic hypotheses, target prioritization (for example, fibroblast subtypes), and biomarker discovery that can inform future diagnostics and therapies.
Key Findings
- Integrated 2.4 million nuclei from 209 adult human hearts across eight anatomical regions and seven health/disease states.
- Performed rigorous harmonization and batch-correction method comparisons to standardize cross-study single-nucleus data.
- Identified robust disease-associated gene signatures in dilated cardiomyopathy across multiple studies.
- Discovered distinct activated fibroblast populations enriched for COL22A1 or TNC with variable prevalence across cardiomyopathies.
Methodological Strengths
- Large-scale cross-study integration with explicit batch-correction benchmarking.
- Coverage of multiple anatomical regions and disease states enables robust comparative analyses.
Limitations
- Cross-sectional transcriptomic data cannot infer causality or temporal dynamics.
- Potential residual batch or sampling biases across contributing studies.
Future Directions: Leverage HeartMap to validate disease-associated cell states in independent cohorts, integrate multi-omics (ATAC, proteomics), and functionally interrogate identified fibroblast subtypes as therapeutic targets.
Cardiovascular disease remains the leading cause of global mortality. Understanding its complexity requires dissecting the heart's cellular landscape. Here we present HeartMap, a comprehensive single-nucleus RNA sequencing atlas of the adult human heart. This resource integrates data from nine studies, encompassing over 2.4 million nuclei, 209 individuals, eight anatomical regions and seven disease and healthy states. After rigorous data harmonization and method comparison of batch correction methods, we characte
2. Real-World Outcomes of Dedicated Leaflet Modification for Bioprosthetic Valve-In-Valve TAVR: A 150-Patient Commercial Experience.
In 150 high-risk valve-in-valve TAVR patients across 28 U.S. centers, dedicated mechanical leaflet splitting achieved 99.3% technical success with low coronary obstruction (2.0%). Despite overall favorable in-hospital safety, serious complications occurred, underscoring the need for careful technique and continued surveillance.
Impact: This study provides the largest real-world assessment of a dedicated leaflet-splitting device to avert catastrophic coronary obstruction during high-risk valve-in-valve TAVR, with adjudicated outcomes.
Clinical Implications: In anatomically high-risk ViV cases, preprocedural CT screening plus dedicated leaflet splitting can expand TAVR eligibility by mitigating coronary obstruction risk. Programs should ensure operator training, hybrid OR readiness, and structured complication monitoring.
Key Findings
- Leaflet splitting was attempted in 145/150 cases and succeeded in 144 (99.3%).
- Predicted acute coronary obstruction risk was present in 87.3% by CT criteria; combined sinus sequestration and direct ostial obstruction in 50.7%.
- Observed coronary obstruction occurred in 3/150 (2.0%); all-cause in-hospital mortality was 2.0%, and conversion to surgery was 1.3%.
Methodological Strengths
- Multicenter consecutive postapproval cohort across 28 centers with VARC-3 adjudication
- CT-based anatomic risk enrichment with prespecified technical and safety endpoints
Limitations
- In-hospital outcomes without longitudinal follow-up limit durability and late safety assessment
- Nonrandomized design with potential selection and operator-learning biases
Future Directions: Prospective comparative studies versus BASILICA and alternative leaflet-modification strategies with longer-term clinical and coronary patency outcomes are needed.
BACKGROUND: Coronary obstruction during valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is infrequent but catastrophic. Mechanical splitting of bioprosthetic leaflets may mitigate this risk, but real-world experience remains limited. OBJECTIVES: The aim of this is to evaluate procedural performance and in-hospital outcomes of a dedicated mechanical leaflet-splitting device in ViV TAVR. METHODS: Consecutive postapproval cases were performed at 28 centers from February to November 2025. Patients were selected for elevated risk based on preprocedural computed tomography criteria, including virtual valve-to-coronary distance ≤4 mm and/or virtual valve-to-sinotubular junction distance ≤3 mm. Procedural outcomes were assessed among patients in whom splitting was attempted; safety outcomes were assessed among all patients in whom the device was introduced. Events were adjudicated using Valve Academic Research Consortium-3 definitions. RESULTS: Among 150 patients (age 78.9 ± 8.5 years; 60.0% female), 95 of 150 (63.3%) underwent ViV TAVR for failed surgical and 55 of 150 (36.7%) for failed transcatheter valves. Computed tomography analysis showed predicted acute coronary obstruction risk in 131 of 150 (87.3%) patients, including combined sinus sequestration and direct ostial obstruction in 76 of 150 (50.7%). Leaflet splitting was attempted in 145 patients and was successful in 144 of 145 (99.3%); dual-leaflet splitting was performed in 83 of 145 (57.2%). Coronary obstruction occurred in 3 of 150 (2.0%; 95% CI: 0.7-5.7). All-cause mortality occurred in 3 of 150 (2.0%; 95% CI: 0.7-5.7), including 2 deaths from left ventricular perforation and 1 after stroke. Conversion to surgery occurred in 2 of 150 (1.3%; 95% CI: 0.4-4.7). CONCLUSIONS: In this early U.S. commercial experience, mechanical leaflet splitting demonstrated high procedural success in an anatomically high-risk ViV TAVR cohort. Serious complications occurred, and longer-term systematic follow-up remains important.
3. Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD.
Using individual-patient data from FIDELITY (n=12,143), causal mediation analyses showed that 4‑month reductions in UACR and SBP jointly mediated 50% (95% CI 21–100) of finerenone’s long-term cardiovascular benefit, with UACR and SBP contributing 39% and 21% individually. Changes in body weight and serum potassium did not mediate benefit.
Impact: This work quantifies actionable intermediate targets (albuminuria and SBP) that carry finerenone’s cardiovascular efficacy, informing monitoring strategies and potential surrogate endpoints.
Clinical Implications: Early UACR and SBP reductions can guide therapeutic monitoring and risk communication in T2D+CKD patients treated with finerenone, whereas body weight and potassium changes should not be interpreted as efficacy surrogates.
Key Findings
- At month 4, finerenone reduced UACR by 32.2% and SBP by 3.6 mmHg versus baseline.
- Causal mediation showed UACR mediated 39% (95% CI 7–71) and SBP 21% (95% CI 3–40) of cardiovascular benefit.
- Joint mediation by UACR and SBP accounted for 50% (95% CI 21–100) of finerenone’s cardiovascular effect.
- Body weight and serum potassium changes did not mediate cardiovascular outcomes.
Methodological Strengths
- Individual patient-level pooled analysis from two large RCTs (FIDELIO-DKD and FIGARO-DKD).
- Pre-specified mediators with robust parametric survival modeling and bootstrap for joint mediation.
Limitations
- Mediation assumes no unmeasured confounding between mediators and outcomes; residual confounding is possible.
- Generalizability limited to T2D with CKD populations under RAS blockade enrolled in the source trials.
Future Directions: Prospectively test UACR/SBP–guided response algorithms, evaluate surrogacy at trial level, and explore heterogeneity of mediation across CKD stages and baseline albuminuria.
BACKGROUND AND HYPOTHESIS: Finerenone reduces cardiovascular events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The cardiovascular benefit emerges within months, before measurable kidney protection, but the early pathways carrying it are not comprehensively quantified. We hypothesized that early reductions in urine albumin-to-creatinine ratio (UACR) and systolic blood pressure (SBP) jointly mediate a substantial proportion of finerenone's long-term cardiovascular benefit,